ATLANTA (August 19, 2020) | Lt. Governor Geoff Duncan recently appointed Sen. Lindsey Tippins (R – Marietta) to serve as a member of the Senate Educating Adult Students Study Committee.
Continue reading “Sen. Lindsey Tippins Appointed to Serve on the Senate Educating Adult Students Study Committee”Senate Study Committee on Financial Efficiency Star Rating Meeting at Capitol
ATLANTA (November 19, 2019) | Sen. Lindsey Tippins (R – Marietta) will host the second meeting of the Senate Study Committee on Financial Efficiency Star Rating (FESR) TOMORROW, November 20, 2019, at 10:00 a.m. in room 450 of the Georgia State Capitol. Continue reading “Senate Study Committee on Financial Efficiency Star Rating Meeting at Capitol”
Senate Study Committee on Financial Efficiency Star Rating Meeting at Capitol
ATLANTA (October 4, 2019) | Sen. Lindsey Tippins (R – Marietta) will host the first meeting of the Senate Study Committee on Financial Efficiency Star Rating (FESR) on Friday, October 11, 2019, starting at 10:00 a.m. in room 450 of the State Capitol.
Continue reading “Senate Study Committee on Financial Efficiency Star Rating Meeting at Capitol”Senate Chairman for the 154th Georgia General Assembly
ATLANTA (January 10, 2017) | The Senate Committee on Assignments has announced the full list of standing committee chairman for the first session of the 154th Georgia General Assembly: Continue reading “Senate Chairman for the 154th Georgia General Assembly”
State Senate Creates Cannabidiol Pilot Program and the “Controlled Substances Therapeutic Research” Act
ATLANTA (March 13, 2015) | Sen. Lindsey Tippins (R – Marietta) led the passage of Senate Bill 185 through the State Senate with a vote of 54-1. This legislation creates a five-year pilot program to be conducted by the Board of Regents to study the effects of cannadbidiol (CBD) on minors with medication-resistant seizures. This legislation will also create the Controlled Substances Therapeutic Research Act. Continue reading “State Senate Creates Cannabidiol Pilot Program and the “Controlled Substances Therapeutic Research” Act”